2021-08-18| Asia-PacificLicensing

China’s InnoCare, Incyte Enter Collaboration And License Deal for Monoclonal Antibody in Greater China

by Kathy Huang
Share To

On August 16th, Chinese-based InnoCare and Incyte announced that Incyte and a subsidiary of InnoCare have entered a collaboration and license agreement for Incyte’s monoclonal antibody tafasitamab.  

According to the agreement, Incyte will receive $35 million upfront payments from InnoCare, plus milestone payments worth up to $82.5 million for the commercialization and development of tafasitamab in Greater China.


Acquiring Incyte’s Newly FDA-approved CD19 Therapy    

Tafasitamab, sold under the brand name Monjuvi, is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody therapy. It was recently approved by the USFDA in July 2020 for use in refractory diffuse large B-cell lymphoma (DBLCL).

 Tafasitamab was originally developed by US biotech company Xencor. In 2010, Xencor granted exclusive worldwide rights of tafasitamab to MorphoSys. In January 2020, MorphoSys and Incyte entered into a licensing deal to further commercialize tafasitamab globally. Incyte has exclusive commercialization rights of tafasitamab outside the United States.

Incyte’s new partner, InnoCare, is equipped with Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib which has received breakthrough therapy designation by the FDA. The addition of tafasitamab to InnoCare’s pipeline is mainly strategic. According to InnoCare, it will test tafasitamab in combination with orelabrutinib, in hopes that the combination will boost the competitiveness of tafasitamab over other CAR-T rival therapies for DBLCL.

“The strategic collaboration with Incyte will not only enhance our strength in the field of hematology and oncology, but also offer us good opportunity to explore the potential clinical benefit of our BTK inhibitor orelabrutinib in combination with tafasitamab,” said Dr. Jasmine Cui, Co-founder, Chairwoman, and CEO of InnoCare.

© All rights reserved. Collaborate with us:
Related Post
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
GV Announces Cooperation with CICC
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
Scroll to Top